332 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This research is critically important because it addresses a significant unmet need for overweight type 2 diabetic patients with IBD, a population facing compounded health challenges. Current IBD therapies are often l…
Understanding ethnic differences in drug response is critical for optimizing dosing and ensuring drug safety globally. Data from studies like this help inform appropriate prescribing practices for diverse populations,…
If successful, this study could highlight a novel therapeutic benefit of semaglutide beyond its established roles in glycemic control and weight management. Identifying an effective pharmacological intervention for di…
While specific numerical outcomes from this completed trial (NCT03882970) are not detailed in the provided record, the study's primary objective was to demonstrate the superior efficacy of tirzepatide in improving gly…
This review underscores the profound and expanding therapeutic potential of GLP-1 receptor agonists, solidifying their role as cornerstone treatments for type 2 diabetes and obesity. The confirmed cardiovascular and r…
This study's design was significant because it aimed to provide a head-to-head comparison of two distinct and highly effective drug classes—a GLP-1 receptor agonist and an SGLT2 inhibitor—in a critical patient populat…
Understanding the precise gastric emptying kinetics in both healthy individuals and GLP-1 agonist users is critically important for optimizing treatment strategies and patient safety. The findings could lead to update…
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
Understanding the interplay between GLP-1 receptor agonists like semaglutide and the ghrelin system is crucial for optimizing obesity treatments. If blocking the ghrelin receptor with LEAP2 proves beneficial, it could…
This research holds significant promise as it investigates a novel approach to treating psoriasis by targeting its metabolic underpinnings, rather than just skin symptoms. If successful, it could demonstrate that Sema…
This study is crucial for enhancing patient safety during surgical procedures for individuals on GLP-1 agonists. The findings will help identify specific patient populations who require additional risk stratification,…
The withdrawal of this study means a valuable opportunity to directly compare these important first-line diabetes treatments has been lost. Had it proceeded, the trial could have provided critical head-to-head data, p…
This research is profoundly important as Type 2 Diabetes (T2D) significantly elevates the risk of severe cerebrovascular events like stroke, and understanding semaglutide's direct impact on brain health is critical. I…
The high and increasing prevalence of adolescent severe obesity underscores the urgent need for more effective and sustainable treatment strategies. If successful, this trial could demonstrate that combining semagluti…
This study is profoundly crucial for validating the cardiovascular benefits of semaglutide 2.4 mg in a real-world setting, offering invaluable data that complements and extends findings from highly controlled clinical…
Understanding the optimal pre-procedural management for patients on GLP-1RAs like semaglutide is critical for patient safety and procedural efficacy during endoscopy. If a one-week discontinuation significantly reduce…
This research is important because it provides real-world evidence for oral semaglutide's effectiveness outside of highly controlled clinical trial settings. Understanding its performance in routine clinical practice,…
This study is significant because it specifically investigates Semaglutide's efficacy and safety in East Asian subjects, addressing a critical gap in demographic representation within clinical trials for overweight an…
The potential findings from this study could be transformative for obesity management, offering a strategy to mitigate the undesirable muscle loss often associated with significant weight reduction. If successful, thi…
This planned study holds significant promise, as it could establish a novel pharmacological strategy to improve outcomes for atrial fibrillation patients with obesity undergoing ablation. If successful, the findings w…
This foundational Phase 1 study is a critical early step in the development of NN9535 (semaglutide), a compound now widely known for its efficacy in type 2 diabetes and obesity. The successful completion of this trial…
This study is significant because it evaluates a novel approach to personalizing semaglutide treatment, which could revolutionize how obesity and excess weight are managed. By providing healthcare professionals with a…
The successful completion of this trial could have significant implications for the treatment landscape of Type 2 Diabetes. If QLG2065 demonstrates comparable efficacy and safety to Ozempic®, it would introduce a new,…
This study is significant because Semaglutide, a GLP-1 receptor agonist, is already approved for obesity and type 2 diabetes, conditions strongly linked to NAFLD. If the results demonstrate efficacy, it could provide …
The resurgence of cocaine use and related mortality underscores an urgent, unmet need for effective treatments. If Semaglutide proves effective in this pilot study, it could offer a novel pharmacological approach to C…
This study holds significant promise for identifying a novel therapeutic approach for alcohol use disorder (AUD), especially in the context of obesity and fatty liver disease, which are highly prevalent comorbidities.…
This pilot study is significant because it explores a novel adjunctive therapeutic strategy for Crohn's disease by targeting metabolic health and weight. If successful, it could demonstrate that GIP/GLP-1 receptor ago…
The withdrawal of this study means a potential avenue for exploring enhanced weight loss and metabolic improvements, particularly through muscle preservation with Bimagrumab alongside Tirzepatide's established effects…
Persistent obesity after bariatric surgery represents a significant clinical challenge, often leading to comorbidities and reduced quality of life. If Tirzepatide proves effective and safe in this specific patient pop…
This pilot study is critically important as it addresses a significant unmet medical need for safe and effective weight management in obese kidney transplant recipients. Successful outcomes could establish Tirzepatide…
Understanding the extrapancreatic effects of GIP and GLP-1 is crucial for optimizing current and developing future treatments for type 2 diabetes and obesity. This research will provide critical insights into why comb…
This study is incredibly significant because it seeks to confirm if tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for weight management, can directly improve long-term health outcomes beyond just…
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to address both obesity and methamphetamine use disorder simultaneously represents a significant advancement in addiction medicine and metabolic he…
Obtaining real-world data on Tirzepatide is paramount for understanding its performance and tolerability outside the highly controlled environment of earlier clinical trials. This study will provide invaluable insight…
The potential to preserve lean mass during GLP-1 induced weight loss is crucial for improving long-term health outcomes and metabolic function in individuals with obesity. Preventing muscle loss can enhance strength, …
The provided research record is a study protocol description from ClinicalTrials.gov and, as such, does not contain specific efficacy or safety results from the trial. The study, NCT06445075, is listed as COMPLETED, i…
The findings of this study are crucial for enhancing patient safety during surgical procedures for individuals on GLP-1/GIP agonists. If standard fasting guidelines prove insufficient, it could lead to revised pre-ope…